← boothcheck

Is CBT overvalued?

boothcheck doesn't label CBT overvalued or undervalued, and it doesn't publish a fair value. It shows what the price assumes instead. At today's price, CBT is priced for growth of -3.6%, and an operating margin near 7.1% versus the 16.3% it earns today. The price is justified by relative-multiple and growth-DCF. The more the price assumes beyond what Cabot Corporation has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from Cabot Corporation's SEC EDGAR filings via a reverse-DCF inversion. Last analyzed June 27, 2026.

Implied growth-3.6%
For about
Margin needed7.1%
Margin today16.3%
Price vs asset value1.46x
Price vs earnings power1.27x
Price vs peer multiples1.16x
Price vs forward growth1.12x
Read the full CBT report →
Get boothcheck's read on what CBT's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.